Access cutting-edge bladder cancer treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.
Access bladder cancer specialists in New Brunswick at no cost
This study follows strict safety protocols and ethical guidelines
All study-related bladder cancer treatment provided free
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 participants who do not have cancer in situ (CIS) but do have high grade papillary urothelial cancer. Eligible patients will be enrolled to receive up to 13 cycles of monthly combination of monalizumab and durvalumab. Both
Sponsor: John Sfakianos
Check if you qualify for this bladder cancer clinical trial in New Brunswick, NJ
If you're searching for bladder cancer treatment options in New Brunswick, NJ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.